Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

The Calandra Report: X-Factor stocks

Thom Calandra Thom Calandra, www.thomcalandra.com
0 Comments| December 30, 2014

{{labelSign}}  Favorites
{{errorMessage}}

Click to enlarge

December 30, 2014


At last, X-factor time: stocks that end in X are special this week.

Or shall we say 2x, as in doubling in the space of hours -- on millions of shares exchanged. Our special situations are getting a choose one: ski-lift; face lift; gift lift.

The very definition of Special Situation, in the financial world, makes it almost a sure thing that these rapid, small-company gainers will continue their parabola into 2015. In many ways, these companies -- Sysorex Global, BioCryst Pharma, Natcore Technology -- are our candidates for Illumina status. Illumina is the genomics data company that made many of us here in California wealthy beyond our wildest dreams.

Please go to:

https://thomcalandra.com/?p=41152

For the actionable bits of this X-file, that is. For TCR subscribers only, please.

See: Why Sysorex, BioCryst & Others Are Enriching TCR

-- Thom Calandra

See: a thomcalandra.com home for our expanding TCR family.

THE CALANDRA REPORT

$129 yearly: Does Not Recur

THE CALANDRA REPORT

$129: Will Recur Yearly

Thom Calandra & TCR are researchers and investors. They are not registered investment advisers, nor do they wish to be. The research and material they offer to subscribers are meant as editorial opinion.



{{labelSign}}  Favorites
{{errorMessage}}

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today

Featured Company